ReviewExpert review of molecular diagnostics2016
Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma.
Review in Expert review of molecular diagnostics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- Assessment of Exhaled Breath Condensate for ALK, RET, ROS1, and NTRK1 Fusion Transcript Detection in NSCLC: Comparison With Tissue and Liquid Biopsy Samples.Thoracic cancer · 2025Article
- Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer.Science advances · 2023Article
- A Systems Biology Approach for Addressing Cisplatin Resistance in Non-Small Cell Lung Cancer.Journal of clinical medicine · 2023Article
- Nanotechnology - a robust tool for fighting the challenges of drug resistance in non-small cell lung cancer.Beilstein journal of nanotechnology · 2023Review
- Clinical and Economic Impact of Upfront Next-Generation Sequencing for Metastatic NSCLC in East Asia.JTO clinical and research reports · 2022Article
- Complex Oncological Decision-Making Utilizing Fast-and-Frugal Trees in a Community Setting-Role of Academic and Hybrid Modeling.Journal of clinical medicine · 2020Article
- Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies.Journal of clinical medicine · 2020Review
- Next-generation sequencing and its clinical application.Cancer biology & medicine · 2019Article
- Kinesin Family Member 18A (KIF18A) Contributes to the Proliferation, Migration, and Invasion of Lung Adenocarcinoma Cells In Vitro and In Vivo.Disease markers · 2019Article
- Isoform specific gene expression analysis of KRAS in the prognosis of lung adenocarcinoma patients.BMC bioinformatics · 2018Article
- The Genetic/Non-genetic Duality of Drug 'Resistance' in Cancer.Trends in cancer · 2018Review
- S100A16, a promising candidate as a prognostic marker for platinum-based adjuvant chemotherapy in resected lung adenocarcinoma.OncoTargets and therapy · 2017Article
- Liquid biopsy in the practice of neo-oncology.Journal of thoracic disease · 2016Article
- Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?International journal of molecular sciences · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAdvances in the biology of non-small-cell lung cancer, especially adenocarcinoma, reveal multiple molecular subtypes driving oncogenesis. Accordingly, individualized targeted therapeutics are based on mutational diagnostics. AREAS COVERED: Advances in strategies and techniques for individualized treatment, particularly of adenocarcinoma, are described through literature review. Approved therapies are established for some molecular subsets, with new driver mutations emerging that represent increasing proportions of patients. Actionable mutations are de novo oncogenic drivers or acquired resistance mediators, and mutational profiling is important for directing therapy. Patients should be monitored for emerging actionable resistance mutations. Liquid biopsy and associated multiplex diagnostics will be important means to monitor patients during treatment. Expert commentary: Outcomes with targeted agents may be improved by integrating mutation screens during treatment to optimize subsequent therapy. In order for this to be translated into impactful patient benefit, appropriate platforms and strategies need to be optimized and then implemented universally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.